Neo adjuvant chemotherapy by Docetaxel + S-1 for resentable gasric cabcer

Neo adjuvant chemotherapy by Docetaxel + S-1 for resentable gasric cabcer - NAC DS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015632

Enrollment

Registered

2014-11-07

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Neo adjuvant chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. adenocarcinoma 2. radical operation is possible by protcol operation 3. Stage IIB, IIIA, IIIB, IIIC patients except for distant metastasis 4. 20 < age <75 5. No preoperative treatment, such as radiotherapy, chemotherapy and hormone therapy 6. ingestionable patient 7. PS 0-1 8. without seriou complication 9. patient with consent

Exclusion criteria

Exclusion criteria: 1. Active double cancer. 2. Administration contraindication of TS-1 3. Continuous use of flucytosine, phenytoin or warfarin potassium 4. History of severe drug allergy (over grade 3) 5. Severe complications 6. infection or acute infectious disease 7. HBV or HCV positive 8. Severe watery diarrhea 9. Female who are pregnant, nursing, suspected of being pregnant or hope to become pregnant during the study period. 10. No birth-control 11. Psychosis or Psychiatric disorder 12. Sever edema to treat 13. History of severe peripheral nerve disorder (over grade 2) 14. HIV positive 15. Patients judged inappropriate for the study by their physicians

Design outcomes

Primary

Measure	Time frame
feasibility	—

Countries

Japan

Contacts

Public ContactNaoyuki Hanari

Graduate school of Medicine, Chiba University Frontier Surgery

naohana718@faculty.chiba-u.jp043-226-2110

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026